Pathologic diagnosis of lung cancer – recent developments
Author:
- 8 November 2023
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 36 (1) , 57-62
Abstract
Purpose of review: Diagnosis of lung cancer has previously been based on the evaluation of resection specimen. However, approximately 80% of lung cancers are diagnosed in stage IV. Targeted therapy has changed the practice of pathology. Diagnosis is usually based on small biopsies or even needle aspirations. Subtyping is important, as a molecular classification has to be added. Recent findings: Molecular analysis has to be done in adenocarcinomas and on some of the rarer carcinoma types. Molecular analysis of squamous cell carcinomas should be done in never or former smokers, as they might present with targetable oncogenes. The same applies for adenosquamous carcinomas. Both high-grade neuroendocrine carcinomas should be subtyped. These subtypes might become relevant for new treatment options, currently investigated. Subtyping is done by immunohistochemistry with antibodies for ASCL1, NeuroD1, and POU2F3. In carcinoids, molecular investigation can better define cases with a higher risk of recurrence and metastasis. Summary: Diagnosis of lung cancer is most often done on small biopsies or cytological preparations. Only a minimal number of tissues or cellular material is used for diagnosis. A considerable portion is reserved for molecular analysis. Molecular investigation is important in adenocarcinomas, but also for other rare tumor types.Keywords
This publication has 24 references indexed in Scilit:
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasNature Genetics, 2015
- Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic CharacterizationsJournal of Thoracic Oncology, 2015
- Lung Adenocarcinomas: Comparison Between Mice and Men2015
- MEN1Gene Mutation and Reduced Expression Are Associated With Poor Prognosis in Pulmonary CarcinoidsThe Journal of Clinical Endocrinology & Metabolism, 2014
- NUT Midline CarcinomaAmerican Journal of Surgical Pathology, 2012
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Bronchiolar columnar cell dysplasia—genetic analysis of a novel preneoplastic lesion of peripheral lungVirchows Archiv, 2003
- The position of pulmonary carcinoids within the spectrum of neuroendocrine tumors of the lung and other tissuesGenes, Chromosomes and Cancer, 2002
- Relationship between epstein-barr virus and lymphoepithelioma-like carcinoma of the lung: A clinicopathologic study of 6 cases and review of the literatureHuman Pathology, 2001
- Morphological and immunohistochemical study of typical and atypical carcinoids of the lung with clinico-pathological correlationEndocrine-Related Cancer, 1994